- A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 Academic Article GET IT
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
Times cited: 7
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 1064
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Annals of Oncology.
Times cited: 386
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European Journal of Cancer Part A: General Topics.
Times cited: 10
- Brain metastasis initial presentation of breast cancer: DNA flow cytometric comparison of two sites. Breast Disease. 1990 Academic Article